What question did this study set out to answer?

This study evaluates the short-term real-world effectiveness and safety of Mirikizumab in ulcerative colitis patients.

P0907Short-term effectiveness and safety of Mirikizumab in ulcerative colitis: real-world evidence from the ENEIDA registry of GETECCU

View Full Paper

Ask AI

Bookmark

This study evaluates the short-term real-world effectiveness and safety of Mirikizumab in ulcerative colitis patients.
Included patients with ulcerative colitis from the ENEIDA registry receiving Mirikizumab.
Assessed clinical disease activity using the partial Mayo score (pMS).
Evaluated clinical remission at 8 and 12 weeks post-treatment.
Clinical remission rates were 32% at week 8 and 37% at week 12.
Patients with prior exposure to fewer treatment modalities had higher remission rates (61.5% for 1 MoA).
Significant decreases in faecal calprotectin and pMS were observed by week 12.

No takes yet. Share an insight, caveat, or question.

Real-world evidence reveals Mirikizumab's short-term effectiveness in ulcerative colitis, suggesting reliable clinical outcomes.

Casbas et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark